Apellis Pharmaceuticals receives Australian approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy

News
Article

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.

(Image Credit: AdobeStock/Alexey Novikov)

(Image Credit: AdobeStock/Alexey Novikov)

Apellis Pharmaceuticals has announced the Therapeutic Goods Administration (TGA) in Australia has approved pegcetacoplan (Syfovre) for the every-other-month treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.

Jeffrey Eisele, PhD, chief development officer at Apellis commented on the approval in a press release from the company.

"The approval of SYFOVRE marks a significant milestone for GA patients across Australia. For the first time, Australians with GA will have a treatment to slow the progression of this irreversible form of vision loss,” said Eisele. “Building on the success in the US, we are excited to bring Syfovre to even more patients who are impacted by this devastating disease.”

Syfovre was approved by the FDA in early 2023, which at the time was also the first in the country just as it is in Australia. According to the company, more than 75,000 Australians are currently living with GA. Robyn Guymer, AM, deputy director, Centre for Eye Research Australia commented on the treatment saying, “As a retina specialist, I have seen how GA often takes away a person’s ability to read, drive, and even see faces of their loved ones. The approval of Syfovre is a historic moment full of hope for the Australian GA community, who have been waiting for a treatment.”

The Australian approval is based on results from the company’s Phase 3 OAKS and DERBY studies at 24 months in which treatment with both every-other-month and monthly Syfovre was shown to slow GA progression and showed a generally well-tolerated safety profile.

References:
  1. Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA). Press Release. Published January 27, 2025. Accessed January 27, 2025.https://investors.apellis.com/news-releases/news-release-details/apellis-receives-approval-syfovrer-pegcetacoplan-australia

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.